New entrants (i.e., Mark Cuban Cost Plus Drugs), plus innovative models from disruptors (i.e., Amazon RxPass) will push continued reform of the drug purchasing and PBM landscape, while outcomes-based arrangements will be a dominant strategy among payers to help control drug spending, specifically on high cost, specialty medications.
New entrants (i.e., Mark Cuban Cost Plus Drugs), plus innovative models from disruptors (i.e., Amazon RxPass) will push continued reform of the drug purchasing and PBM landscape, while outcomes-based arrangements will be a dominant strategy among payers to help control drug spending, specifically on high cost, specialty medications.
See how rule of three’s strategic services can support you and your healthcare team.
